Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in children and adolescents with fibrosing interstitial lung disease
NL-OMON61345Phase 3Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nerandomilast in pulmonary fibrosis (PF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Steady-state AUCT,SS and Treatment-emergent adverse event by Week 26. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON61345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61345.